Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teriflunomide Extension Study in Relapsing Multiple Sclerosis
NCT00811395Phase 2Completed
- Sponsor
- Sanofi
- Start
- Oct 2007
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of teriflunomide in multiple sclerosis (MS) (6 arms), sponsored by Sanofi. Primary endpoints: Overview of Adverse Events at 64 weeks and Liver Function: Number of Participants With Potentially Clinically Significant Abnormalities at 64 weeks. Started Oct 2007; status: completed.
02
Drugs
teriflunomide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00811395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00811395.